Disclosure of Information

Sareum Holdings PLC
16 August 2007


For immediate release                                            16 August 2007





                              SAREUM HOLDINGS PLC

                          ("Sareum" or the "Company")



                                  AIM Rule 26




Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business confirms that, for the purposes of AIM Rule 26, the Company's website
address is www.sareum.co.uk.









For further information:


Sareum Holdings                                                  01223 497700

Tim Mitchell, Chief Executive Officer

Buchanan Communications                                          020 7466 5000

Tim Anderson, Mary-Jane Johnson

Grant Thornton Corporate Finance                                 020 7383 5100

Philip Secrett, Colin Aaronson





Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange